The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach of its clot-busting hardware.

Black Diamond Therapeutics and Ideaya Biosciences are mulling over registrational trials for their lead assets after receiving encouraging phase 2 data in lung and eye cancers, respectively.

After a series of trials and tribulations, Ventyx Biosciences has received a $27 million boost from Sanofi, money that is expected to extend the biotech’s cash runway into the second half of 2026.

Context Therapeutics is building up its bank of bispecific antibody candidates. The Philadelphia-based company is paying $11 million upfront for a T-cell engaging antibody from BioAtla, according to a Sept. 23 SEC filing.

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its investors.

After CEO Kevin Lobo promised earlier this summer a “bullish” M&A pipeline, Stryker is following through with its seventh deal announcement of the year so far.

Athira Pharma has been on a bumpy road in recent years, and, now, the company is restructuring and shedding weight to try to keep the journey going.

Masimo’s long-running proxy fight has come to a close, at least for now. During the company’s annual meeting, shareholders elected two board members nominated by activist investor Politan Capital Management—and ousted the medtech’s founder and CEO, Joe Kiani, in the process.

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medtronic.

Achilles Therapeutics has torn up its strategy. The British biotech is stopping work on its clinical-phase cell therapy, looking into deals with groups working on other modalities and preparing to lay off staff.